🔎 BRAIN Registry: Exploring how brain cancer is diagnosed and treatment across Australia, from initial presentation to outcomes and survival rates. A fabulous example by Dr Gately of how the #GibbsLab research can be utilised to answer novel research questions. 🌟

🔎 BioBrain: A robust biobank of brain cancer tissue, used to explore the use and creation of organoid models, help guide treatment selection and potentially identify novel treatments for patients.

Amazing work by Dr Lucy Gately from #GibbsLab at #COGNO25. Her presentation on the EMBRACE program won Most Outstanding Oral Presentation 🌟. EMBRACE is working to enhance multi-site brain cancer research, utilising the #GibbsLab BRAIN Registry and the BioBrain project.

🔎 The potential benefit for future patients is a major driver to trial participation. 🔎 Reimbursement alone may not drive broader representation and participation in trials. Further research is needed to better understand how funding plays into participation.

This interesting research came out of the CO-DESIGN study, a survey investigating consumer perspectives and involvement in clinical research. The study captured a cross-section of community views on the consumer experience.

Congratulations to Dr Grace Gard of the #GibbsLab for winning the best oral prize at MOGA ASM 2025 for her presentation on understanding motivations of patient participation in research or in considering unfunded medication. 🌟

Utilising ARORA data, this new research has been able to validate clinical trial data and will help guide treatment decisions in routine care.

The ARORA Registry commenced in 2020 and tracks HR+, HER2+ advanced breast cancer patients across Australia from presentation to treatment and outcomes. Fabulous to see this great use of #GibbsLab registries.👏

🔍Check out some of the amazing research that has been done utilising the ARORA Registry data! Presented at Breast Cancer Trials 2025 ASM last week, this poster reflects one of the #GibbsLab registries in action.

💡 Explore innovative solutions for improving patient outcomes. 🔍 Share groundbreaking research and treatment strategies. 🤝 Foster international collaboration to accelerate progress. Can't wait to see you there! 🔗 More info and registration:

By bringing together leading experts, researchers, clinicians, policymakers, and healthcare professionals, it aims to accelerate progress through collaboration, innovation, and the sharing of knowledge.

📍 Location: Urban Station, 189 rue de Bercy 75012 Paris, France 📅 Date: June 26th, 2025 This important event will lay the foundation for a global initiative to tackle the most complex and urgent challenges in oncology — with a focus on cancers with the poorest prognosis.

#GibbsLab is thrilled that Dr Belinda Lee has been invited as a speaker at the international conference "Poor Prognosis Cancers: From Resignation to Revolution", organized by Institut national du cancer ( INCa) and NCC Japan, as part of the #G7Cancer initiative.

🌟 A collaboration led by Dr Steven David at PMCC and Dr Michelle White at Monash, with the Radiation Oncology Departments and project managed by the team at #GibbsLab. 🌟This recent publication builds on the abstract presented at ASTRO 2023 and sets the stage for AVATAR-2.

“This is an endorsement of the capacity of registry trials – an agile and economic option for trials that otherwise wouldn’t get done and can deliver impressive results of interest” - Dr Steven David, co-principal investigator

The AVATAR trial is a great example of the collaborative work the #GibbsLab is known for! Now published 🔥 Read more about the study here: https://t.co/rMwYyTrVHQ

Tumour organoids make it possible to test a range of chemotherapy drugs and can help identify optimal drug combinations, improving personalised patient treatment. #gibbslab

Check out Prof. Peter Gibbs talking about some of the amazing work going on in the #gibbslab right now! 🌟 https://t.co/3An4EuBEch

🔍 Dr Vanessa Wong presented a poster on the work she is doing with Dr Colin Williams. Utilising the TRACC registry, they are investigating whether mCRC patients under 35y demonstrate distinct characteristics and outcomes relative to older patients.

Fabulous work by the #gibbslab at ESMO Asia 2024 last weekend!🌟 🔍Lab head Prof. Peter Gibbs co-chaired a session on shaping the future of metastatic colorectal cancer. His presentation explored novel strategies he is investigating for the treatment and management of mCRC.